Evidence map›Paper›PMID 34813393›Full record

ArticleEpigenetics2022

Genetic and epigenetic analysis of the serotonin 2A receptor in the context of cocaine abuse.

Aysheh Alrfooh, Ryan M Smith

Open access · greenAbstract read
In one paragraph

Article in Epigenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. 5-HTPharmacological reviews · 2025
    Review
  2. Alternative splicing in addiction.Current opinion in genetics & development · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Aysheh AlrfoohDepartment Of Pharmaceutical Sciences And Experimental Therapeutics, College Of Pharmacy, University Of Iowa, Iowa City, IA, USA.ORCID 0000-0002-5227-3305
Ryan M SmithDepartment Of Pharmaceutical Sciences And Experimental Therapeutics, College Of Pharmacy, University Of Iowa, Iowa City, IA, USA.ORCID 0000-0002-0774-7583
University of Iowa · US

Funding

The University of Iowa Clinical and Translational Science AwardKL2TR002536 · NCATS · UNIVERSITY OF IOWA · PI BASSUK, ALEXANDER G · 2018 to 2022
$3.3M
NCATS NIH HHS KL2 TR002536
6 · The paper itself

Abstract

Despite more than 2 million American cocaine users monthly, there is no approved drug for treating cocaine use disorder. Cocaine use disorder has a multifactorial aetiology, including both genetic and environmental factors. Both cocaine use and genetic variations demonstrably alter DNA methylation and gene expression in the brain in a complex manner. How these factors interact in the context of cocaine abuse in humans is unknown. We propose that we can identify potential drug targets for treating cocaine use disorders by examining genetic, epigenetic, and expression changes in the brains of individuals that abused cocaine. In this study, we identified the interaction between the epigenetics changes (DNA CpG methylation) and genetic variants (SNPs) in the

Indexed as

CocaineCocaine-Related DisordersDNADNA MethylationEpigenesis, GeneticHumansPolymorphism, Single NucleotideProtein IsoformsReceptor, Serotonin, 5-HT2ARNA, MessengerCocaineDNAHTR2A protein, humanProtein IsoformsReceptor, Serotonin, 5-HT2ARNA, Messengercocaine addictionDNA methylationgeneticsHTR2Ars6311rs6313serotoninsingle nucleotide polymorphisms

Identifiers

PMID34813393
PMCPMC9543049
OpenAlexW3217455168

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.